Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Endologix Inc (ELGX)

Endologix Inc (ELGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States

Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc. (OTC: ELGXQ) ("Endologix" or the "Company") today announced the first implant of its recently approved ALTO(R) endograft...

ELGX : 0.2200 (-23.88%)
ELGXQ : 0.0199 (-24.33%)
Delisting of Securities of KemPharm, Inc.; Endologix, Inc.; VIVUS, Inc.; SAExploration Holdings, Inc.; Ascena Retail Group, Inc.; and Global Eagle Entertainment Inc. from The Nasdaq Stock Market

The Nasdaq Stock Market announced today that it will delist the common stock of KemPharm, Inc. KemPharm, Inc.'s common stock was suspended on May 21, 2020 and has not traded on Nasdaq since that time....

ASNA : 0.6063 (-15.67%)
ELGX : 0.2200 (-23.88%)
KMPH : 1.0970 (-2.05%)
NDAQ : 127.33 (+0.05%)
SAEX : 0.3000 (-51.61%)
VVUS : 0.4665 (-10.29%)
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

, /PRNewswire/ -- a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced two key hires: , joining...

ELGX : 0.2200 (-23.88%)
Endologix Announces Departure of CFO and Appointment of Interim CFO

Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer (CFO),...

ELGX : 0.2200 (-23.88%)
Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System

Endologix(R) Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the...

ELGX : 0.2200 (-23.88%)
Endologix (ELGX) Reports Q1 Loss, Tops Revenue Estimates

Endologix (ELGX) delivered earnings and revenue surprises of -19.40% and 0.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ELGX : 0.2200 (-23.88%)
Endologix: 1Q Earnings Snapshot

IRVINE, Calif. (AP) _ Endologix Inc. (ELGX) on Monday reported a loss of $18.1 million in its first quarter.

ELGX : 0.2200 (-23.88%)
Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

Endologix(R) Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory...

ELGX : 0.2200 (-23.88%)
Endologix Reports First Quarter 2020 Financial Results

Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020....

ELGX : 0.2200 (-23.88%)
Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after...

ELGX : 0.2200 (-23.88%)
The Global Vascular Graft Market is expected to grow from USD 2,985.07 Million in 2018 to USD 4,895.07 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.32%

Reportlinker.com announces the release of the report "Global Vascular Graft Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05871605/?utm_source=GNW...

CAH : 53.77 (-0.37%)
ELGX : 0.2200 (-23.88%)
MDT : 113.31 (-0.66%)
TRUMF : 40.8900 (+1.59%)
Endologix Appoints Tim A. Benner as Chief Commercial Officer

Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Tim A. Benner to succeed John...

ELGX : 0.2200 (-23.88%)
Endologix Announces Preliminary Financial Results for First Quarter 2020

Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the first quarter ended...

ELGX : 0.2200 (-23.88%)
Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to two newly hired employees...

ELGX : 0.2200 (-23.88%)
SmileDirectClub (SDC) Catches Eye: Stock Jumps 13.3%

SmileDirectClub (SDC) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.

ELGX : 0.2200 (-23.88%)
SDC : 12.10 (+0.58%)
Endologix Adds Jane E. Kiernan to its Board of Directors

Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jane E. Kiernan to its board...

ELGX : 0.2200 (-23.88%)
Endologix Receives FDA Approval for Alto Abdominal Stent Graft System

Endologix(R) Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has received approval from the United States...

ELGX : 0.2200 (-23.88%)
Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee...

ELGX : 0.2200 (-23.88%)
Is the Options Market Predicting a Spike in Endologix (ELGX) Stock?

Investors need to pay close attention to Endologix (ELGX) stock based on the movements in the options market lately.

ELGX : 0.2200 (-23.88%)
Endologix Announces Debt Restructuring Addressing 2020 Maturities

Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with...

ELGX : 0.2200 (-23.88%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar